Atea Pharmaceuticals, Inc. (AVIR) is a Biotechnology company in the Healthcare sector, currently trading at $5.80. It has a SharesGrow Score of 45/100, indicating a mixed investment profile with 2 out of 7 criteria passed.
Analyst consensus target is AVIR = $7 (+18.6% upside).
Valuation: AVIR trades at a trailing Price-to-Earnings (P/E) of -2.9 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.1.
Net income is $158M (loss), growing at -11.7%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).
Balance sheet: total debt is $843,000 against $275M equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 7.82 (strong liquidity). Debt-to-assets is 0.3%. Total assets: $315M.
Analyst outlook: 1 / 4 analysts rate AVIR as buy (25%) — mixed sentiment.
SharesGrow 7-Criteria breakdown: Value 92/100 (Pass), Growth 15/100 (Fail), Past 0/100 (Fail), Health 100/100 (Pass), Moat 28/100 (Fail), Future 46/100 (Partial), Income ?/100 (Fail).
